BDNF Related to Cognition and Fitness in Men with Coronary Artery Disease
At the 51st Annual Meeting of the National Institute of Mental Health’s New Clinical Drug Evaluation Unit (NCDEU) in 2011, Walter Swardfager and colleagues from Toronto, Ontario presented a study indicating that brain-derived neurotrophic factor (BDNF) concentrations in blood are associated with cognitive performance and cardiopulmonary fitness in people with coronary artery disease.
In 88 mostly male subjects with a mean age of 63 years, cardiopulmonary fitness was directly correlated with BDNF in blood as well as higher scores of cognition on two tests, the mini mental status exam and the digit symbol coding task. The investigators concluded that better fitness, psychomotor processing speed, and overall cognition were consistent with a hypothesis that BDNF protects midbrain dopaminergic neurons against inflammatory neurodegenerative processes.
Blood levels of interleukin 6, a measure of inflammatory cytokines, were associated with lower mini mental status scores in a multivariate analysis that controlled for BDNF levels.
Editor’s note: BDNF appears to be necessary for long-term learning and memory. Meta-analyses indicate that BDNF levels are low in depression and improve with euthymia. Many mood stabilizers including lithium, valproate, carbamazepine, and lamotrigine and most types of antidepressants are able to increase BDNF. The current findings linking BDNF with better cardiopulmonary fitness and cognition continue to emphasize the potential importance of BDNF beyond its role as a marker for depression.
In BNN Volume 12, Issue 3 from 2008, we reported on the data of Schmidt and Duman, which indicated that BDNF administered in a subcutaneous minipump is able to reverse many depressive-like behaviors in an animal model of depression, suggesting that even peripheral BDNF may have a role in the central nervous system.